This study focuses on FDA-approved lipid-lowering drugs, specifically namely 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitors, Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and NPC1-like Niemann-Pick C1–like 1 (NPC1L1) inhibitors, as potential melanoma chemoprevention agents. The gene discussed is HMGCR; the disease is melanoma.